KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Cost of Revenue: 2018-2024

Historic Cost of Revenue for Rigel Pharmaceuticals (RIGL) over the last 7 years, with Dec 2024 value amounting to $18.6 million.

  • Rigel Pharmaceuticals' Cost of Revenue fell 40.78% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.5 million, marking a year-over-year increase of 16.86%. This contributed to the annual value of $18.6 million for FY2024, which is 162.26% up from last year.
  • Per Rigel Pharmaceuticals' latest filing, its Cost of Revenue stood at $18.6 million for FY2024, which was up 162.26% from $7.1 million recorded in FY2023.
  • Rigel Pharmaceuticals' Cost of Revenue's 5-year high stood at $18.6 million during FY2024, with a 5-year trough of $895,000 in FY2020.
  • Moreover, its 3-year median value for Cost of Revenue was $7.1 million (2023), whereas its average is $9.2 million.
  • In the last 5 years, Rigel Pharmaceuticals' Cost of Revenue declined by 1.21% in 2020 and then soared by 306.52% in 2023.
  • Over the past 5 years, Rigel Pharmaceuticals' Cost of Revenue (Yearly) stood at $895,000 in 2020, then grew by 21.01% to $1.1 million in 2021, then spiked by 61.50% to $1.7 million in 2022, then soared by 306.52% to $7.1 million in 2023, then spiked by 162.26% to $18.6 million in 2024.